Artikel
Psychooncological treatment requirement in patients with low-grade glioma
Suche in Medline nach
Autoren
-
Alessandra Ley
- Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
-
Hans-Jakob Steiger
- Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
-
Marcel Kamp
- Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
-
Michael Sabel
- Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
-
Marion Rapp
- Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
| Veröffentlicht: | 2. Juni 2015 |
|---|
Gliederung
Text
Objective: Until now there is no standardized psychooncological assessment that enquires the need for psychooncological treatment for patients with low-grade glioma (LGG). Most of those patients show no symptoms related to their disease but live with the constant knowledge of their diagnosis and the fact that their condition can impair at any time. This may lead to high rates of anxiety and/or depression and reduced health related quality of life.
Method: Patients with histologically confirmed LGG and patients with LGG-suspicious findings in MRI were screened for their psychooncological treatment demand. Three different self-assessment instruments were used (Hospital Anxiety and Depression Scale (HADS), Distress Thermometer (DT), EORTC-QLQ-C30 B20) as well as one external assessment questionnaire (Psychooncological base documentation (Po-Bado)). Screening was assessed perioperatively as well as 3-monthly in the course of disease.
Results: Since October 2013, 105 patients (61 men, 44 women, median age 52 years) could be screened at our neurosurgical department. Diagnosis was neuropathologically confirmed in 80 patients and based on MRI findings in 25 patients. Screening was conspicuous in 52 patients (49.2%), in 39 patients (48.8%) with confirmed diagnosis and in 13 (52%) with suspicious MRI findings.
Regarding the different screening tools, the DT was positive in 36 patients (34.2%, Sensitivity (SEN) 66%, Specificity (SPE): 67%). HADS was positive in 28 patients (26.6%, SEN: 54%, SPE: 73%). PoBado was positive in 19 patients (18.1%, SEN: 37%, SPE: 58%).
In 100 patients results could be correlated to the EORTC questionnaire. Reduced GH as well as reduced QoL and high rates of future uncertainty are found in 47 patients (44.7%). Men and women's demand for psychooncological support appears to be equal.
Conclusions: These results confirmed the emotional distress in association with the diagnosis of LGG. Interestingly, the demand for psychooncological treatment tends to be increased in patients who received neurosurgical treatment. The DT showed the highest sensitivity compared to the HADS and PoBado. Reduced global health and increased future uncertainty seem to correlate with the need for psychooncological treatment.
